[
    [
        {
            "time": "",
            "original_text": "贝达药业一季度业绩增152.36% 厄洛替尼专利即将过期风险增加",
            "features": {
                "keywords": [
                    "贝达药业",
                    "一季度业绩",
                    "152.36%",
                    "厄洛替尼",
                    "专利过期",
                    "风险增加"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业一季度业绩增152.36% 厄洛替尼专利即将过期风险增加",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]